Skip To Main Content

Artikelen

Sort by

Filters

Resetten
  • Therapeutische gebieden
cGVHD criteria

cGVHD criteria

Guidelines

Guidelines

What is Toujeo?

What is Toujeo?

How to use Toujeo<sup>®</sup>?

How to Use Toujeo®

Spotlight on AD—the role key cytokines play and a look at the factors that contribute to this condition

Atopic dermatitis pathophysiology: type 2 inflammation & cytokines

Beneath the skin of patients with AD—type 2 inflammation and the cytokines involved.

Taming Diabetes: A Daily Challenge for Martin and His Family

Taming Diabetes: A Daily Challenge for Martin and His Family

Follow 8-year-old Martin and his family as they navigate daily life with type 1 diabetes, from meal adaptations to school activities, showing resilience and optimism.

Living with T1D for 25 Years: Philippe's Inspiring Journey

Living with T1D for 25 Years: Philippe's Inspiring Journey

At the dawn of his fifties, Philippe has tamed the diabetes he has lived with for over 25 years, along with his initial fear of injections. For him, this disease represents "a turning point, not an end." He leads a life "like everyone else," multiplying passions and fully enjoying every moment.

Cumulative Life Course Impairment (CLCI) in Atopic Dermatitis

Cumulative Life Course Impairment (CLCI) in Atopic Dermatitis

BRIGHT publication

BRIGHT publication

Advancing the treatment: Meeting the challenge of uncontrolled Atopic Dermatitis (AD) and Prurigo Nodularis (PN)

Advancing Treatment for Uncontrolled AD and PN: New Approaches

As we continue to advance in our understanding and treatment capabilities, our response to uncontrolled AD and PN becomes more effective, paving the way for a future where patients can lead healthier, more comfortable lives8.

Underneath the skin

Underneath the Skin: Hidden Challenges of Uncontrolled AD and PN

What are the hidden challenges of living with uncontrolled Atopic Dermatitis (AD) and Prurigo Nodularis (PN)?

Lipid management in patients with diabetes mellitus

Lipid management in patients with diabetes mellitus

Key principles of lipid management (LDL-C in particular) in accordance with the 2019 ESC/EAS Guidelines for the management of dyslipidaemias, and the 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.